Minimally invasive therapy of lower urinary tract symptoms.
The establishment of guidelines, pharmacologic therapies, improved understanding of lower urinary tract symptoms (LUTS) versus benign prostate hyperplasia (BPH), respect for patient-centered goals, and improved discrimination of the patient with occult prostate cancer have empowered change in the management of LUTS. These developments have allowed urologists to recognize the limitations of transurethral prostatectomy as the gold standard and search for "ideal therapies" to provide treatments with an improved relief of symptoms, decreased complication rate and cost, to correct BPH-associated morbidities and prevent future morbidities. Prognostic parameters and their ability to predict progression may be important in the future of LUTS management and selection of therapy.
Donnell
Robert F
RF
The Department of Urology, The Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226, USA. rdonnell@mcw.edu
D001905:Botulinum Toxins / Q000627:therapeutic use; D017115:Catheter Ablation / Q000379:methods; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D008872:Microwaves / Q000627:therapeutic use; D019060:Minimally Invasive Surgical Procedures; D009465:Neuromuscular Agents / Q000627:therapeutic use; D018579:Patient Selection; D011470:Prostatic Hyperplasia / Q000628:therapy*; D053448:Prostatism / Q000628:therapy*; D015607:Stents; D020728:Transurethral Resection of Prostate / Q000379:methods
D009465:Neuromuscular Agents; D001905:Botulinum Toxins